提名委員會職權範圍 (於二零二六年二月四日生效) 4.1 提名委員會應履行以下責任： (1) 至少每年檢討董事會的架構、人數及組成(包括技能、知識 及經驗方面)、協助董事會編制董事會技能表，並就任何為 配合本公司的公司策略而擬對董事會作出的變動提出建議； (2) 物色具備合適資格可擔任董事的人士，並挑選提名有關人 士出任董事或就此向董事會提供意見； 5. 匯報程序 1.1 提名委員會(「提名委員會」)是閩信集團有限公司(「本公司」)董 事會(「董事會」)屬下的小組委員會，由董事會授權代表其審議載 於下文第 4 段的事宜。 1.2 提名委員會的職責包括但不限於協助董事會檢討董事會的架構、 人數及組成、挑選具備合適資格的董事人選、評核獨立非執行董事 的獨立性、編制董事會技能表、支援本公司定期評估董事會表現。 2. 行政架構 2.1 提名委員會由董事會委任不少於三名成員組成，其中大部份須為 非執行董事，並至少需有一名不同性別的董事。 2.2 提名委員會主席(「主席」)須由董事會委任，並須由董事會主席或 獨立非執行董事擔任。任何會議若出現主席未克出席的情況，提名 委員會將從出席成員中選出一位代理主席主持會議。 2.3 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 閩信集團有限公司 | | | | 呈交日期: | 2026年2月3日 | | | | I. 法定/註冊股本變動 | 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00222 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 597,257,252 0 597,257,252 增加 / 減少 (-) 本月底結存 597,257,252 0 597,257,252 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.2 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 閩信集團有限公司 | | | | 呈交日期: | 2026年1月2日 | | | | I. 法定/註冊股本變動 | 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00222 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 597,257,252 | | 0 | | 597,257,252 | | 增加 / 減少 (-) | | ...

Core Viewpoint - Minxin Group (00222) has entered into a loan agreement with a bank, securing a non-committed revolving credit facility of up to HKD 390 million, effective December 11, 2025 [1] Group 1: Loan Agreement Details - The bank has the discretion to modify, cancel, or suspend the credit facility without prior notice, including the cancellation of any unused credit [1] - The bank can also change, modify, or supplement any terms of the loan agreement at its discretion, which may lead to the immediate termination of the credit facility if the company disagrees [1] - Any outstanding amounts under the credit facility will become immediately due and payable if the company does not agree to the changes [1]

Group 1 - The company, Minxin Group (00222), has entered into a loan agreement with a bank, providing a non-committed revolving credit facility of up to HKD 390 million [1] - The bank retains the right to modify, cancel, or suspend the credit facility at its discretion without prior notice, including the cancellation of any unused credit [1] - If the company disagrees with any changes made by the bank to the loan agreement, the credit facility will be immediately terminated, and all outstanding amounts will become due [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 按上市規則第 13.18 條規定作出之公告 本公告乃由閩信集團有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》（「《上市規 則》」）第13.18條項下的披露規定 而作出。 於2025年12月11日，本公司作為借款人與一間銀行（「銀行」）作為貸 款人簽訂一份貸款協議（「貸款協議」），銀行同意向本公司提供上限 為港幣390,000,000元的非承諾性循環授信額度（「授信 額度」）。銀行 可隨時在不經事先通知的情況下全權酌情修改、取消或暫停授信額度， 包括 但不限於 取消任 何未動 用 的 授信及 宣佈任 何 未償 還 款 項即 時到期 及償 還。銀行 亦可全 權酌情 通 過 向本公 司發出 通 知變 更 、 ...

Core Viewpoint - The stock price of Tailong Pharmaceutical (600222) experienced significant volatility after the announcement of a potential change in ownership, initially rising to the limit but then plummeting to a drop limit, ultimately closing down 4.43% on the day of resumption of trading [1][4]. Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd. (Tairong Investment), is planning to transfer shares, which may lead to a change in control of the company [3][6]. - Tairong Investment intends to transfer 50.1 million shares to Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. (Jiang Pharmaceutical Holdings) at a price of 11.043 CNY per share, representing a premium of over 28% compared to the pre-suspension price of 8.58 CNY per share [3][6]. - Following the completion of the transaction, the controlling shareholder will change from Tairong Investment to Jiang Pharmaceutical Holdings, and the actual controller will shift from the Zhengzhou High-tech Industrial Development Zone Management Committee to the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [3][6]. Group 2: Financial Performance - During Tairong Investment's tenure, Tailong Pharmaceutical's performance has been inconsistent, with a revenue increase of 22.2% in 2022, the highest growth since 2018, but a net profit loss [7]. - In the first three quarters of 2024, Tailong Pharmaceutical's revenue declined to 1.187 billion CNY, a year-on-year decrease of 11.47%, and the net profit attributable to shareholders was 25 million CNY, down 12.36% year-on-year [4][7].

Group 1 - The core point of the news is that Tai Long Pharmaceutical experienced significant stock price volatility, opening with a limit increase before dropping sharply and then recovering slightly by the end of the trading day [1] - After a week of suspension, Tai Long Pharmaceutical announced that its controlling shareholder, Tai Rong Investment, had reached an agreement with relevant parties regarding a potential change in company control, leading to the resumption of trading on December 9 [3] - On December 8, Tai Rong Investment and Zhengzhou Zhongsheng Industrial Group, a shareholder with over 5% stake, reached an agreement with Jiang Pharmaceutical Holdings regarding a share transfer and governance matters, which includes the transfer of 8.73% of the company's shares at a price of 11.043 yuan per share, totaling 553 million yuan [4] Group 2 - The agreement will establish a consistent action relationship between Tai Rong Investment and Jiang Pharmaceutical Holdings regarding major company decisions, solidifying Jiang Pharmaceutical Holdings' control over Tai Long Pharmaceutical [4] - If the share transfer and related agreements proceed smoothly, Jiang Pharmaceutical Holdings will hold 7.37% of the shares after the first transfer, and through the agreement, will control a total of 14.37% of the shares, resulting in a change of the controlling shareholder from Tai Rong Investment to Jiang Pharmaceutical Holdings [4]

Market Overview - Major indices opened lower but quickly rebounded, with the ChiNext Index and STAR Market 50 Index turning positive [1] - CPO concept stocks continued to perform strongly, with Zhongci Electronics hitting the daily limit, and Shaanxi Huada and Dekeli rising over 10% [1] - Innovative drug concept stocks gained traction, with Haichuang Pharmaceutical-U rising over 14%, and Zhaoyan New Drug, Peking University Pharmaceutical, and Chengdu Xian Dao increasing over 5% [1] - The shipbuilding sector saw broad gains, with China Shipbuilding and China Power rising over 3% [1] - Film and cinema stocks were active, with Ciweng Media and Bona Film Group rising over 6%, followed by Huace Film and China Film [1] New Stock Offering - Yuanchuang Co., Ltd. opened for subscription today, issuing a total of 19.6 million shares at a price of 24.75 yuan, with an earnings per share ratio of 12.93 times [1] - The company specializes in the research, production, and sales of rubber track products, primarily used in agricultural and engineering machinery [1] - Yuanchuang holds the top market share in the domestic rubber track industry according to recent reports [1] Private Placement Announcements - Three companies announced private placement plans on December 9, with Purun Co., Ltd. seeing a significant price increase after resuming trading [2] - Tailong Pharmaceutical plans to issue up to 74.61 million shares at 6.09 yuan each, aiming to raise 454 million yuan for working capital and debt repayment [2] - Following a share transfer agreement, Tailong's controlling shareholder will change to Jiang Pharmaceutical Holdings, with the actual controller becoming the Jiangxi State-owned Assets Supervision and Administration Commission [2] Mergers and Acquisitions - Purun Co., Ltd. plans to acquire 49% of Noah Changtian's equity through a combination of share issuance, convertible bonds, and cash [3] - Yongda Co., Ltd. intends to purchase 49% of Jinyuan Equipment's equity from Ge Yanming, with plans to issue shares to specific investors for funding [3] Financing Activities - As of December 8, the market's financing balance reached 2.48 trillion yuan, an increase of 186.32 billion yuan from the previous trading day [4] - A total of 617 stocks saw net financing purchases exceeding 10 million yuan, with 49 stocks exceeding 100 million yuan [4] - Shenghong Technology topped the list with a net purchase of 1.254 billion yuan, followed by Tianfu Communication and Xiangshang Chip Creation [4] Sector Analysis - In the sector analysis, electronics, non-ferrous metals, and non-bank financials were prominent among stocks with net purchases exceeding 100 million yuan [5] - The average financing balance as a percentage of market capitalization was 4.67%, with C Moer-U having the highest ratio at 11.35% [5] - Other stocks with high financing balance ratios included Jianqiao Technology, Zhishang Technology, and Dongfang Caifu [5]

Market Overview - Major indices opened lower but quickly rebounded, with the ChiNext Index and the Sci-Tech 50 Index turning positive [1] Sector Performance - CPO concept stocks continued to perform strongly, with Zhongci Electronics hitting the daily limit, and Shaanxi Huada and Dekeli rising over 10% [2] - The innovative drug sector saw gains, with Haichuang Pharmaceutical-U increasing over 14%, and Zhaoyan New Drug, Peking University Pharmaceutical, and Chengdu XianDao rising over 5% [3] - The shipbuilding sector experienced broad gains, with China Shipbuilding and China Power both rising over 3% [4] - Film and cinema stocks were active, with Ciweng Media and Bona Film Group rising over 6%, followed by Huace Film and China Film [5] New Stock Offerings - Yuanchuang Co., Ltd. opened for subscription today, issuing a total of 19.6 million shares at a price of 24.75 yuan, with an earnings per share ratio of 12.93 [6] - The company specializes in the research, production, and sales of rubber track products, holding the top domestic market share according to recent reports [7] Private Placement Announcements - Three companies announced private placement plans, with Purun Co., Ltd. seeing a significant rise of over 17% after resuming trading [8] - Tailong Pharmaceutical plans to issue up to 74.6 million shares at 6.09 yuan each, raising approximately 454 million yuan for working capital and debt repayment [8] Financing Activities - As of December 8, the market's financing balance reached 2.48 trillion yuan, an increase of 186.32 billion yuan from the previous trading day [10] - A total of 49 stocks saw net purchases exceeding 100 million yuan, with Shenghong Technology leading at 1.254 billion yuan [10] - The electronics, non-ferrous metals, and non-bank financial sectors saw significant net purchases, with 18, 5, and 5 stocks respectively [11]